These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Tc-99m HMDP (hydroxymethylene diphosphonate): a radiopharmaceutical for skeletal and acute myocardial infarct imaging. II. Comparison of Tc-99m hydroxymethylene diphosphonate (HMDP) with other technetium-labeled bone-imaging agents in a canine model. Bevan JA, Tofe AJ, Benedict JJ, Francis MD, Barnett BL. J Nucl Med; 1980 Oct; 21(10):967-70. PubMed ID: 6252299 [Abstract] [Full Text] [Related]
4. Tc-99m HMDP (hydroxymethylene diphosphonate): a radiopharmaceutical for skeletal and acute myocardial infarct imaging. I. Synthesis and distribution in animals. Bevan JA, Tofe AJ, Benedict JJ, Francis MD, Barnett BL. J Nucl Med; 1980 Oct; 21(10):961-6. PubMed ID: 6252298 [Abstract] [Full Text] [Related]
5. Radiation absorbed dose from technetium-99m-labeled bone imaging agents. Task Group of the Medical Internal Radiation Dose Committee, The Society of Nuclear Medicine. Weber DA, Makler PT, Watson EE, Coffey JL, Thomas SR, London J. J Nucl Med; 1989 Jun; 30(6):1117-22. PubMed ID: 2544697 [No Abstract] [Full Text] [Related]
6. Accumulation of Tc-99m phosphorus compounds in medullary carcinoma of the thyroid: report of two cases. Shigeno C, Fukunaga M, Yamamoto I, Dokoh S, Morita R, Hino M, Torizuka K. Clin Nucl Med; 1982 Jun; 7(6):297-8. PubMed ID: 6282522 [No Abstract] [Full Text] [Related]
7. Skeletal scintigraphy with technetium diphosphonate in multiple myeloma--a comparison with skeletal x-ray. Lindström E, Lindström FD. Acta Med Scand; 1980 Jun; 208(4):289-91. PubMed ID: 6449830 [Abstract] [Full Text] [Related]
8. New diphosphonate compounds for skeletal imaging: comparison with methylene diphosphonate. Subramanian G, McAfee JG, Thomas FD, Feld TA, Zapf-Longo C, Palladino E. Radiology; 1983 Dec; 149(3):823-8. PubMed ID: 6316414 [Abstract] [Full Text] [Related]
9. The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. Pollen JJ, Witztum KF, Ashburn WL. AJR Am J Roentgenol; 1984 Apr; 142(4):773-6. PubMed ID: 6230903 [Abstract] [Full Text] [Related]
10. The role of routine followup bone scans after definitive therapy of localized prostatic cancer. Huben RP, Schellhammer PF. J Urol; 1982 Sep; 128(3):510-2. PubMed ID: 6214643 [Abstract] [Full Text] [Related]
11. Diphosphonates in the evaluation of metabolic bone disease. Fogelman I, Smith ML. Clin Rheumatol; 1982 Mar; 1(1):41-4. PubMed ID: 6236012 [Abstract] [Full Text] [Related]
13. Bone scintigraphy in plasma-cell myeloma. A prospective study of 70 patients. Bataille R, Chevalier J, Rossi M, Sany J. Radiology; 1982 Dec; 145(3):801-4. PubMed ID: 6292996 [Abstract] [Full Text] [Related]
15. Myocardial uptake. An unexpected finding in an oncology follow-up. Boedecker RA, Blake DG, Sty JR, Riegert MR. Clin Nucl Med; 1983 Aug; 8(8):358-9. PubMed ID: 6226469 [No Abstract] [Full Text] [Related]
16. [Skeletal scintigraphy for the observation of course and treatment of carcinoma of the prostate ]. Pabst HW, Langhammer H, Schmid L, Sintermann R. Rofo; 1981 Jul; 135(1):44-9. PubMed ID: 6288532 [Abstract] [Full Text] [Related]
17. The technetium phosphate bone scan in the diagnosis of osteomyelitis in childhood. Howie DW, Savage JP, Wilson TG, Paterson D. J Bone Joint Surg Am; 1983 Apr; 65(4):431-7. PubMed ID: 6300132 [Abstract] [Full Text] [Related]